Posts by John

Europe’s drug development sector faces a decline in R&D and market access. Discover why experts are demanding an overhaul to improve patient care.

Bulgaria is launching a strategic review to reform its heavily regulated pharma market, aiming to boost drug access and streamline medicinal approvals.

New research shows a breakthrough combination therapy significantly delays multiple myeloma progression and enhances survival outcomes for patients.

New research shows how model-informed dosing of carvedilol and nebivolol can safely improve cardiovascular treatment outcomes for patients with cirrhosis.

Discover how organoid technology is revolutionizing cancer research, bridging the gap between clinical trials and personalized, patient-centered therapy.

Neumora axes its lead depression drug after Phase 3 failure, while the FDA approves Colorado's state plan to import lower-cost prescription drugs from Canada.

The EMA is adjusting its regulatory framework to align with the new EU Biotech Act, aiming to accelerate the approval of innovative biological therapies.

Eli Lilly reports positive early-stage clinical results for its latest JAK inhibitor, signaling a potential breakthrough in treating inflammatory diseases.

A new targeted drug strategy is showing potential to double survival rates for pancreatic cancer patients, marking a major breakthrough in oncology care.

New analysis reveals major reporting gaps in EU clinical trials, threatening medical transparency and patient safety. Read the implications for researchers.